Skip to main content

Table 1 Baseline features of the study population

From: Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders

 Patients (N = 144)Group A (N = 101)Group B (N = 43)p-value
Sex, males.n(%)71 (49.3%)42 (41.6%)29 (67.4%)0.006
Age, years, mean (SD)60 ± 13,564.9 ± 11.750.6 ± 12.1< 0.001
Risk Factorsn(%)
IDU37 (25.7%)17 (16.9%)20 (46.5%)< 0.001
Heterosexual10 (7.0%)8 (7.9%)2 (4.7%)0.720
MSM1 (0.7%)01 (2.3%)0.290
 Nosocomial38 (26.4%)31 (30.6%)7 (16.3%)0.150
Unknown58 (40.2%)45 (44.6%)13 (30.2%)0.138
HCV Genotypesn(%)
1a32 (22.2%)17 (16.8%)15 (34.9%)0.020
1b51 (35.4%)44 (43.6%)7 (16.3%)0.002
237 (25.7%)31 (30.7%)6 (13.9%)0.038
318 (12.5%)5 (4.9%)13 (30.2%)< 0.001
46 (4.2%)4 (4%)2 (4.7%)1.000
Duration of HCV infection, years (range)18 (10–25.5)20 (11–26)17 (9–23)0.199
Log 10 HCV-RNA, IU/mL, median (range)6.00 (5.48–6.52)5.9 (5.6–6.5)6.2 (5.6–6.6)0.095
Liver stiffness, Kpa, mean (SD)10,8 ± 9,911.5 ± 11.29.1 ± 5.20.518
Previous failure,n(%)32 (22.2%)29 (28.7%)3 (7.0%)0.004
INF-based tx31283 
DAAs-based tx110 
Fibrosis stage,n(%)
F0-F278 (54.1%)51 (50.5%)27 (62.8%)0.203
F324 (16.7%)19 (18.8%)5 (11.6%)0.338
F442 (29.2%)31 (30.7%)11 (25.6%)0.689
FIB-4 score median (range)2.02 (1.40–3.35)2.2 (1.5–3.4)1.6 (1.2–2.9)0.009
APRI score median (range)0.40 (0.60–1.22)0.6 (0.4–1.2)0.7 (0.4–1.2)0.315
MELD score median (range)7 (6.5–8.5)7.0 (6.0–8.0)7.0 (6.0–7-0)0.923
Child-Pugh classn(%)
 A142 (98.6%)100 (99.1%)42 (97.7%)0.510
 B2 (1.4%)1 (0.99%)1 (2.3%)0.510
Cirrhosis,n(%)46 (31.9%)34 (33.66%)12 (27.9%)0.562
Oesophageal varices or portal hypertension,n(%)15 (10.4%)11 (10.89%)4 (9.3%)1.000
Type of HCV therapyn(%)
 SOF + RBV7 (4.8%)6 (5.9%)1 (2.3%)0.670
 SOF + SMV ± RBV5 (3.5%)4 (3.9%)1 (2.3%)1.000
 SOF + LDV ± RBV21 (14.6%)15 (14.9%)6 (13.9%)1.000
 SOF + DCV ± RBV13 (9.0%)10 (10%)3 (7%)0.750
 OMB + PTV/r + DAS ± RBV15 (10.4%)15 (14.9%)00.006
 OMB + PTV/r + RBV2 (1.4%)2 (1.9%)01.000
 SOF + VEL ± RBV37 (25.7%)15 (14.9%)22 (51.2%)< 0.001
 GLE + PIB24 (16.7%)17 (16.8%)7 (16.3%)1.000
 GRZ + EBR ± RBV20 (13.9%)17 (16.8%)3 (7%)0.186
Duration of therapyn(%)
8w20 (13.9%)15 (14.9%)5 (11.6%)0.794
12w101 (70.1%)67 (66.3%)34 (79.1%)0.164
16w6 (4.2%)4 (3.9%)2 (4.65%)1.000
24w17 (11.8%)15 (14.9%)2 (4.65%)0.097
Addition of RBVn(%)33 (22.9%)24 (23.74%)9 (20.9%)0.829
ALT, UI/L, median (range)50 (30–80)47 (26.5–78.5)58 (43–93)0.029
Total bilirubin, mg/dL, median (range)0.62 (0.45–0.85)0.65 (0.47–0.82)0.60 (0.40–0.87)0.323
Serum creatinine, mg/dL, median (range)0.78 (0.61–0.93)0.78 (0.60–0.95)0.78 (0.62–0.90)0.795
Platelets (×10^9/L), median (range)183.5 (140.5–217.5)184 (145–219)182 (137–214)0.936
Albumin, mg/dL, median (range)4.0 (3.7–4.2)4.0 (4.7–4.2)4.0 (3.8–4.1)0.976
Body mass index, median (range)25.3 (23.3–28.7)25.5 (23.8–29.1)25.1 (22.4–27.4)0.936
Patients with at least 1 other comorbidity, n (%)101 (70.10%)79 (78.2%)22 (51.2%)0.002
Diabetes,n(%)20 (13.9%)16 (15.8%)4 (9.3%)0.431
Hypertension,n(%)61 (42.4%)53 (52.5%)8 (18.6%)< 0.001
HBsAg positive,n(%)2 (1.4%)02 (4.7%)0.087
HIV infected,n(%)19 (13.2%)9 (8.9%)10 (23.3%)0.030
N aviremic pts on ART, n (%)19 (100%)9 (100%)10 (100%)1.000
CD4+(cells/μl) median (range)85 (42–171)98 (50–171)83.5 (42–186.5)0.903
CDC-C Stage n (%)7 (4.8%)4 (3.9%)3 (7%)0.650
  1. Legend: IDU Injecting drug user, MSM Man who have sex with man, INF Interferon, DAA Direct antiviral agent, SOF Sofosbuvir, RBV Ribavirin, SMV Simeprevir, LDV Ledipasvir, DCV Daclatasvir, OMB Ombitasvir, PTV/r Paripatrevir/ritonavir, DSV Dasabuvir, VEL Velpatasvir, GLE Glecaprevir, PIB Pibrentasvir, GRZ Grazoprevir, EBR Elbasvir, ALT Alanine aminotransferase, ART Antiretroviral therapy